A multi-center, randomized, open-label, controlled, one-year trial to measure the effect of zoledronic acid and alendronate on bone metabolism in post menopausal women with osteopenia and osteoporosis

Trial Profile

A multi-center, randomized, open-label, controlled, one-year trial to measure the effect of zoledronic acid and alendronate on bone metabolism in post menopausal women with osteopenia and osteoporosis

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jul 2012

At a glance

  • Drugs Alendronic acid; Zoledronic acid
  • Indications Bone resorption; Metabolic bone diseases; Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Acronyms ROSE
  • Sponsors Novartis
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Jul 2012 Results from the secondary endpoint analyses (quality of life, adherence and patient preference) published in Osteoporosis International.
    • 01 Feb 2012 Results published in Osteoporosis International.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top